Advertisement
U.S. markets open in 3 hours 5 minutes

VolitionRx Limited (VNRX)

NYSE American - NYSE American Delayed Price. Currency in USD
0.8722-0.0878 (-9.15%)
At close: 04:00PM EDT
0.9306 +0.06 (+6.70%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9600
Open0.9312
Bid0.8402 x 2200
Ask1.0000 x 900
Day's Range0.8722 - 0.9700
52 Week Range0.5500 - 2.1000
Volume66,482
Avg. Volume187,755
Market Cap68.63M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateMar 19, 2024 - Mar 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VNRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VolitionRX Limited
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • PR Newswire

    Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

    VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test.

  • InvestorPlace

    Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

    The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these biotech stocks that will provide high retu

  • PR Newswire

    Volition Issues Business Review 2023

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key highlights from the past year.